Literature DB >> 12386249

Prevalence and socio-economic aspects of chronic kidney disease.

Jürgen Bommer1.   

Abstract

The incidence and prevalence of end-stage renal disease (ESRD) are rising in Europe, the USA, and Japan. Prevalence is rising more steeply than incidence, due mostly to improved efficiency of treatment -patients are surviving longer. Hypertension and diabetes, the main causes of progression from chronic kidney disease (CKD) to ESRD, are becoming more frequent in the general population and make a large contribution to the rising incidence of ESRD. More effective therapies for other conditions have introduced new complications for patients with CKD, thereby also increasing the incidence of ESRD. Increased survival in the general population is reflected in the greater number of elderly people requiring care for ESRD. ESRD is a great economic burden and one that will increase as the incidence and prevalence of the disease increase. This needs to be considered when planning treatment. Prevention and early treatment of hypertension and diabetes will have the greatest impact on the future prevalence of ESRD and the costs associated with its treatment.

Entities:  

Mesh:

Year:  2002        PMID: 12386249     DOI: 10.1093/ndt/17.suppl_11.8

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  12 in total

1.  Hyperhomocysteinaemia as a potential marker of early renal function decline in middle-aged Asian people without chronic kidney disease.

Authors:  Young Jin Tak; Dong Wook Jeong; Yun Jin Kim; Sang Yeoup Lee; Jeong Gyu Lee; Sang Heon Song; Kwang Soo Cha; Yang Ho Kang
Journal:  Int Urol Nephrol       Date:  2016-01-02       Impact factor: 2.370

2.  The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.

Authors:  George W Carides; Shahnaz Shahinfar; Erik J Dasbach; William F Keane; William C Gerth; Charles M Alexander; William H Herman; Barry M Brenner
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  [Therapy and prophylaxis of renal failure].

Authors:  V M Brandenburg; B Heintz; J Floege
Journal:  Internist (Berl)       Date:  2003-07       Impact factor: 0.743

4.  Inequalities in the Global Burden of Chronic Kidney Disease Due to Type 2 Diabetes Mellitus: An Analysis of Trends from 1990 to 2019.

Authors:  Nóra Kovács; Attila Nagy; Viktor Dombrádi; Klára Bíró
Journal:  Int J Environ Res Public Health       Date:  2021-04-28       Impact factor: 3.390

5.  Reverse iontophoresis of urea in health and chronic kidney disease: a potential diagnostic and monitoring tool?

Authors:  Leonard M Ebah; Ian Read; Andrew Sayce; Jane Morgan; Christopher Chaloner; Paul Brenchley; Sandip Mitra
Journal:  Eur J Clin Invest       Date:  2012-03-12       Impact factor: 4.686

6.  Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes.

Authors:  M Flaquer; M Franquesa; A Vidal; N Bolaños; J Torras; N Lloberas; I Herrero-Fresneda; J M Grinyó; J M Cruzado
Journal:  Diabetologia       Date:  2012-03-30       Impact factor: 10.122

Review 7.  Macrophage in chronic kidney disease.

Authors:  Roser Guiteras; Maria Flaquer; Josep M Cruzado
Journal:  Clin Kidney J       Date:  2016-10-05

8.  Exploring macrophage cell therapy on Diabetic Kidney Disease.

Authors:  Roser Guiteras; Anna Sola; Maria Flaquer; Anna Manonelles; Georgina Hotter; Josep M Cruzado
Journal:  J Cell Mol Med       Date:  2018-11-08       Impact factor: 5.310

9.  The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study.

Authors:  Yuki Tomonaga; Lorenz Risch; Thomas D Szucs; Patrice M Ambühl; Patrice M Ambuehl
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

10.  Dietary Habit and Other Risk Factors of Chronic Kidney Disease Among Patients Attending Dessie Referral Hospital, Northeast Ethiopia.

Authors:  Foziya Mohammed Hussien; Hamid Yimam Hassen
Journal:  Int J Nephrol Renovasc Dis       Date:  2020-05-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.